Document is current

Article History

Accepted: 27 December 2022

First Online: 30 January 2023

Declarations

:

: No external funding was used in the preparation of this article.

: Lodovico Balducci is a consultant for Aileron. Alan List is a consultant for Aileron. Claire Falandry has no conflicts of interest that are directly relevant to the content of this article.

: No ethics approval was needed for a review article.

: This is a review article and did not require the participation of human subjects.

: Not applicable.

: No dataset was generated or analyzed during the current study.

: Not applicable.

: LB generated the idea of this review and wrote the original draft. CF reviewed and revised the geriatric portion. Alan List reviewed and revised the information related to growth factors, ALRN-6924, and trilaciclib, and highlighted the proactive approach that is the most novel aspect of this review.